NeoStem Names Robert Dickey IV As CFO - Quick Facts

8/19/2013 7:59 AM ET

NeoStem Inc. (NBS) announced that it has appointed Robert Dickey IV as Chief Financial Officer, effective today.

NeoStem stated that Larry May, the company's long-time Chief Financial Officer, is assuming the newly-created position of Vice President, Strategic Initiatives, and will assist Dickey in the transition as well as focus on the company's various strategic activities.

Dickey has over 15 years of management experience at life sciences companies, including positions as a CFO, COO and CEO and board member, following a career as an investment banker.

He has specific expertise in financing, M&A, partnering/licensing transactions and project management, as well as international experience.

Dickey is joining NeoStem from Hemispherx Biopharma, Inc. where he served as Senior Vice President. Prior to Hemispherx , Dickey was Senior Vice President, Chief Financial Officer and Business Unit Manager at StemCyte Inc. Other management experience includes leadership positions at Protarga Inc, and Locus Pharmaceuticals. Previously, he spent 18 years as an investment banker, 14 of those at Lehman Brothers, with a background split between M&A and capital markets transactions across a variety of industries.

British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast.

Electronic Arts Inc. (EA) on Thursday reported an increase in profit for the first quarter, reflecting continued strong digital revenues, with both earnings and revenues topping Wall Street estimates. However, shares of the company fell over 4 percent, after having detailed a weak outlook.
Redwood...